SCHEMBL14102447

SCHEMBL14102447

CC(C)CCC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.61
ACHE P22303 9/20 0.58
BCHE P06276 2/20 0.56
ALDH1A1 P00352 1/20 0.54
CXCR4 P61073 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3891051 0.85 CCR3 (0.55) CCR3ACHEBCHE
SCHEMBL8245441 0.84 ACHE (0.67) CCR3ACHEALDH1A1CXCR4
SCHEMBL20257208 0.84 CCR3 (0.53) CCR3ACHEBCHEALDH1A1CXCR4
SCHEMBL15140944 0.83 CCR3 (0.73) CCR3ACHEBCHEALDH1A1CXCR4
SCHEMBL69200 0.82 CCR3 (0.67) CCR3ACHEBCHEALDH1A1CXCR4
SCHEMBL9163513 0.82 CCR3 (0.48) CCR3ACHEBCHE
SCHEMBL3107807 0.82 CCR3 (0.71) CCR3ACHEBCHEALDH1A1CXCR4
SCHEMBL5234223 0.81 ACHE (0.56) CCR3ACHECXCR4
SCHEMBL22751978 0.81 ACHE (0.58) CCR3ACHEBCHEALDH1A1CXCR4
SCHEMBL17562354 0.81 ACHE (0.58) CCR3ACHEBCHEALDH1A1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
US-9546153-B2 Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-17 US disclosed
US-20150274696-A1 BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2015-10-01 US disclosed
WO-2008094208-A2 PROTEIN KINASE TARGETED THERAPEUTICS NORTHWESTERN UNIVERSITY (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 CCR3 1597/4885ACHE 3442/4885BCHE 2328/4885
US-20150274696-A1 BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS IRAK4, IRAK1, IRAK3 CCR3 1411/4885ACHE 4610/4885BCHE 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.